<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="31454"><DrugName>TEI-D1614</DrugName><DrugSynonyms><Name><Value>TEI-D1614</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="20331">Teijin Ltd</CompanyOriginator><CompaniesSecondary><Company id="20331">Teijin Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="31454" type="Drug"><TargetEntity id="302312" type="siDrug">TEI-D1614</TargetEntity></SourceEntity><SourceEntity id="20331" type="Company"><TargetEntity id="4295877394" type="organizationId">Teijin Ltd</TargetEntity></SourceEntity><SourceEntity id="14" type="ciIndication"><TargetEntity id="G30" type="ICD10"/><TargetEntity id="331.0" type="ICD9"/><TargetEntity id="10012271" type="MEDDRA"/><TargetEntity id="D000544" type="MeSH"/><TargetEntity id="-1268969445" type="omicsDisease"/><TargetEntity id="101" type="siCondition"/></SourceEntity><SourceEntity id="1238" type="Action"><TargetEntity id="275" type="Mechanism">Drugs Acting on Prostanoid Receptors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="14">Alzheimers disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="1238">Prostanoid receptor modulator</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2005-09-02T17:16:49.000Z</LastModificationDate><ChangeDateLast>2005-09-02T17:16:49.000Z</ChangeDateLast><AddedDate>2000-11-08T13:08:14.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="20331"&gt;Teijin&lt;/ulink&gt; was investigating TEI-D1614, an &lt;ulink linkType="Drug" linkID="9980"&gt;isocarbacyclin&lt;/ulink&gt; derivative, for the potential treatment of Alzheimer's disease [&lt;ulink linkType="reference" linkID="388791"&gt;388791&lt;/ulink&gt;].  However, no development had been reported since that time.&lt;/para&gt;&lt;para&gt;TEI-D1614  was a  follow-up compound to &lt;ulink linkType="Drug" linkID="9023"&gt;TEI-3356&lt;/ulink&gt; (qv).  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2000, it was reported  at the 30th Annual Meeting of the Society for Neuroscience, New Orleans, LA, that TEI-D1614 reversed beta-amyloid-induced impairment in a rat model of passive avoidance at 12 fmol/day by icv infusion. The mechanism of TEI-D1614 was not fully characterized, but it had a low propensity to cause cardiovascular side effects. TEI-D1614 showed equivalent efficacy when administered by sc infusion (2.5 mg/kg), indicating that it crosses the blood-brain barrier. &gt;TEI-D1614  was also reported to dose-dependently stimulate neurite outgrowth in neuro 2A cells [&lt;ulink linkType="reference" linkID="388791"&gt;388791&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;TEI-D1614 is a prostacyclin derivative.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2002-05-08T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="20331">Teijin Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="14">Alzheimers disease</Indication><StatusDate>2000-11-08T00:00:00.000Z</StatusDate><Source id="388791" type="CONFERENCE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01609"><Name>Prostanoid receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><PatentFamilies><PatentFamily id="1839898" number="WO-00110433" title="Neuropathy improvers containing nitrogenous compounds as the active ingredient"/><PatentFamily id="1913792" number="WO-00110445" title="Neuropathy remedies"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Osaka Bioscience Institute" id="18711"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Teijin Ltd" id="20331"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>